This Special Communication discusses case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable locally advanced NSCLC. ja.ma/4aL5YND

Most viewed in the last 7 days from JAMA Oncology:

Do prostate cancer screening pathways that incorporate MRI and targeted biopsies outperform strategies that rely solely on PSA testing and systematic biopsy?

Presented at #EAU24

ja.ma/4awLFDp

Using ePROs to prompt direct patient trial invitations resulted in greater enrollment to a symptom-intervention trial than standard of care physician-based referral. ja.ma/4cU8lin Nicholas Verdini Jun J. Mao Erin Gillespie, MD MPH Memorial Sloan Kettering Radiation Oncology

This case report describes an 89-year-old patient with prior cutaneous squamous cell carcinoma who presented with a new isolated metastasis and was subsequently treated with pembrolizumab, which produced a complete clinical response. ja.ma/3VWoXjE

34% of patients with advanced cancer and 29% of caregivers prioritize symptom management over life extension. Interventions to target prognostic awareness & reduce discordant goals of care can help develop realistic expectations. ja.ma/3xqIj64

Findings of this phase 2 nonrandomized trial of patients presenting with HPV-associated unknown primary SCC suggest that an algorithmic surgical approach with transoral robotic surgery may help identify occult primary tumors. ja.ma/43WPq2z

Among 685 breast cancer survivors who were 40 years or under at primary diagnosis and had a lumpectomy or a unilateral mastectomy, 10-year risk of second primary breast was low (2.2%) for those without germline genetic predisposition. ja.ma/3UcmUXj

Substance use disorders (SUD) prevalence is higher among survivors of certain types of cancer, suggests cross-sectional study. This information could be used to identify cancer survivors who may benefit from integrated cancer and SUD care. ja.ma/4957Bnp

Addition of olaparib as maintenance treatment was associated with longer survival in patients with epithelial ovarian cancer with BRCA-like tumors in a secondary biomarker-by-treatment interaction analysis of the PAOLA1 RCT. ja.ma/4aqMOMt

Anti-EGFR rechallenge therapy has promising antitumor activity in patients with refractory circulating tumor DNA RAS/BRAF wild-type metastatic colorectal cancer, particularly with absence of liver metastases. ja.ma/3Ja4Zdk Davide Ciardiello

Most viewed in the last 7 days from JAMA Oncology:

What is the optimal neoadjuvant regimen for patients with operable node-positive, high-risk stage III and IV melanoma?

ja.ma/3vGYxYm

Review examines the race and ethnicity of participants enrolled in pediatric studies conducted in response to written requests from the US FDA for which pediatric exclusivity was granted between 2001 and 2021. ja.ma/4a01Qc3

Decedents with stage IV NSCLC had a median survival in the order of 3.5 months and spent 1 in every 3 days alive interacting with the health care system outside the home. ja.ma/4arUgab

Study suggests that women who inherited PTVs of the 5 major genes for breast cancer disproportionately contributed to the diagnosis of interval breast cancer, and it was mostly associated with BRCA1/2 and PALB2 genes. ja.ma/4a2hkMK

Editorial by Peter B. Bach, MD: Late-Stage Cancer End Points to Speed Cancer Screening Clinical Trials—Not So Fast ja.ma/4cMLTHM #AACR24

In randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types but is not suitable for others, finds meta-analysis of 41 RCTs. ja.ma/49vbh22 #AACR24

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. ja.ma/3J3zZMi #AACR24

This Viewpoint highlights the need for recognition that ovarian cancer affects women from racial and ethnic minority groups worldwide and that the rates of ovarian cancer are increasing in those populations while decreasing among White women. ja.ma/49nFVKz

Most viewed in the last 7 days from JAMA Oncology:

What is the optimal neoadjuvant regimen for patients with operable node-positive, high-risk stage III and IV melanoma?

ja.ma/4cLDqEK

Editorial by Jeffrey Tosoian Jeff Tosoian, MD, MPH, David Penson Dave Penson, and Michigan Pathology Arul Chinnaiyan: A Pragmatic Approach to Prostate Cancer Screening

ja.ma/43Pied3

#EAU24